Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,880.40
(
0.03%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.01
(
4.78%
)
Bitcoin
76,327.86
(
0.57%
)
News Focus
News Focus
Post# of 3757
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WID post# 2369

Monday, 01/28/2008 7:10:25 PM

Monday, January 28, 2008 7:10:25 PM

Post# of 3757
>Look for IDIX presentation of a head-to-head trial of IDX899+Truvada vs Sustiva+Truvada in first- or second-line patients.<

No, the phase-2 trial vs Sustiva has not yet started.

The IDX899 results to be reported at CROI are those for the phase-1b and phase-2a monotherapy studies and a phase-2 drug-interaction study (#msg-25836446). Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote